Two Sigma Advisers
DGX icon

Two Sigma Advisers’s Quest Diagnostics DGX Stock Holding History

Two Sigma Advisers’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,000
Closed -$910K – 2495
2014
Q3 		$910K Buy
+15,000
New +$924K 0.01% 1183
2014
Q1 		– Sell
-6,000
Closed -$321K – 2319
2013
Q4 		$321K Buy
+6,000
New +$356K ﹤0.01% 1864

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Two Sigma Advisers's DGX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,700 shares — an estimated $295K sold.

Two Sigma Advisers first reported a position in DGX in Q3 2013 and held it in 34 quarters. The position peaked at $103M in Q1 2019. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,700 Quest Diagnostics shares in Q1 2026, an estimated $295K.
  • Two Sigma Advisers first reported a position in Quest Diagnostics in Q3 2013 and held it in 34 quarters.
  • Two Sigma Advisers's Quest Diagnostics position peaked at $103M in Q1 2019.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.